

THE UNIVERSITY OF BRITISH COLUMBIA

Curriculum Vitae for Faculty Members

Date: September 19, 2017

Initials:

1. **SURNAME:** TEAL
FIRST NAME: PHILIP
MIDDLE NAME(S): AUBREY

2. **DEPARTMENT/SCHOOL:** MEDICINE/NEUROLOGY,
 Associate member, Division of Vascular Surgery,
 Department of Surgery

3. **FACULTY:** MEDICINE
4. **PRESENT Rank** Clinical Professor,
SINCE: 2007

 2006
 The Sauder Family and Heart and Stroke Foundation of British Columbia
 Professor in Clinical Stroke Research

5. POST-SECONDARY EDUCATION

University or Institution	Degree	Subject Area	Dates
University of Alberta	B.Me.Sc.	Medical Sciences	1968 - 1970
University of Alberta	M.D.	Medicine	1970 - 1974
American Boards of Emergency Medicine	FACEP	Emergency Medicine	1982
Royal College of Physicians & Surgeons of Canada	FRCP(C)	Emergency Medicine	1983
Royal College of Physicians & Surgeons of Canada	FRCP(C)	Neurology	1990

Special Professional Qualifications

1. Internship - Royal Jubilee Hospital, Victoria, BC
 Rotating Internship, 1974-1975
2. Residency - University of British Columbia, Vancouver, BC
 Neurology Resident, 1987-1991
3. Fellowship - New England Medical Center, Tufts University, Boston MA
 Cerebrovascular/Stroke Fellowship, 1991-1992
4. American Boards in Emergency Medicine (ABEM) 1983

5. FRCP(C) Emergency Medicine (Canada) 1983
6. FRCP(C) Neurology 1990

6. EMPLOYMENT RECORD

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
Royal Jubilee Hospital	Active Staff	1975-1986
Victoria General Hospital	Associate Staff	1975-1986
Ministry of Health, Province of British Columbia	Senior Medical Consultant	1985-1986
Tufts University School of Medicine/Spalding Rehabilitation Hospital	Instructor/Assistant Director	1991-1992

(b) *At UBC*

Rank or Title	Dates
Associate Staff, Division of Neurology	1992-1995
Active Staff, Division of Neurology	1995-present
Associate Staff, Dept. of Surgery, Division of Vascular Surgery	1996-present
Consulting Staff, B.C. Children's Hospital	1997-present
Director, Vancouver General Hospital Stroke Program	1992-present
Consulting Staff Whistler Medical Clinic	1998- present

7. TEACHING

(a) ***Areas of special interest and accomplishments:***

Antiplatelet Therapy and antithrombotics

Thrombolysis , tPA, Abciximab, IIb/IIIa antagonists

UBC Recognition of excellence in teaching 1993

Stroke Prevention Strategies for Physicians

Public Awareness Education Regarding Stroke Prevention and Treatment

Acute Stroke Management CME for Physicians

Brain and Behaviour teaching module

Weekly Stroke Rounds for Residents

Office mentor medical students, neurology residents

June 2007 The Fay R Dirks Award
For Excellence in Teaching
University of British Columbia

2007-2008 Best Doctors in Canada

(b) ***Continuing Education Activities***

1. Attendance at weekly Neuroscience Grand Rounds
2. Attendance at weekly Neurology Case Rounds
3. American Academy of Neurology - Annual Meetings
4. Canadian Stroke Consortium – Annual Investigators Meeting
5. Self directed readings
6. American Heart Association - Annual Stroke Meeting
8. European Stroke Conference - Annual Meeting
9. Canadian Congress of Neurosciences - Annual Meeting
10. Numerous small CME events annually
11. Weekly neuroscience rounds VGH weekly

Full list available on request. I average over 200 hours per year in CME activities

(c) *Visiting Lecturer (indicate university/organization and dates)*

See Attached

8. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) *Areas of special interest and accomplishments*

My focus in cerebrovascular disease has been in the areas of stroke prevention, acute stroke management, thrombolysis, antithrombotic therapies, and neuroprotection strategies. I have been extensively involved in the planning, organization, and conduct of clinical trials.

My research activities have focussed on the planning, design, review, and execution of Phase II and Phase III clinical trials. I have served on multiple international steering committees and advisory boards. I have been the Chair of Steering committees, the International PI, have served on the executive triads of steering committees. The Vancouver General Hospital is recognized internationally for the successful conduct of clinical trials both grant funded as well as industry sponsored.

I have served on international, national, and local boards including the International Stroke Society, the World Stroke Federation, the Canadian Stroke Strategy, the Canadian Stroke Consortium, the Western Stroke Society, the Western Vascular Society, the Heart and Stroke Foundation of BC and Yukon, and the BC Stroke Recovery Association. My presentation to the Health Protection Branch resulted in the initial approval for tPA use for acute ischemic stroke in Canada.

On a clinical level, I maintain a busy tertiary stroke referral practice; I developed and continue to run the VGH Stroke Prevention Clinic. I developed the VGH acute stroke response system. The VGH was the first hospital in Canada to use and approve the use of tPA for acute ischemic stroke.

The I am recognized nationally and internationally as a stroke expert as evidenced by my international talks.

I have clinical interest and expertise in the neurological complications of trauma, traumatic brain injury, and traumatic injuries to the central and peripheral nervous system.

I see and treat patients with headache disorders and general neurological conditions including epilepsy, degenerative disease of the nervous system and peripheral nerve problems.

I have been continuously engaged in educational efforts at the medical student, resident, and post-graduate level and give more than 50 formal talks on an annual basis. I have given invited talks in Canada, the USA, Italy, France, the UK, Germany, Australian, Japan, China, Taiwan, and Argentina. I have accepted future invitations to speak and chair a session at the World Federation of Neurology in Australia in November 05 and to speak and chair a session in the World Stroke Congress in Cape Town, South Africa in November 2006.

I served as a Co-organizer for the 5th World Stroke Congress, served as the local organizing Chairman, and served on the International Scientific Committee. I was the Co-chair of the 8th International Symposium Thrombolysis and Acute Stroke Therapy. I continue to be actively involved in the planning and organization of local, national, and international congresses.

Participation in Stroke Treatment Trials:

1. Co-investigator - North American Symptomatic Carotid Endarterectomy Trial (NASCET), 1989-1995
2. Participating physician - Asymptomatic Carotid Artery Stenosis Study (ACAS), 1991-1992
3. Co-investigator - CGS-19755 (NMDA antagonist in acute stroke), 1991-1992
4. Co-investigator - Thrombolytic Therapy in acute Thrombotic/Thromboembolic Stroke, 1991-1992.
5. Principal Investigator - Clopidogrel vs Aspirin in Patients at Risk of Ischemic Event (CAPRIE), 1992-1996
6. Principal Investigator - Applaud SKB 1007
7. Principal Investigator (Vancouver Site) - Selfotel (CGS 19755) Trial for Acute Stroke Therapy, 1995-1996
8. Principal Investigator (Vancouver Site) - Prospective Multicenter Dose-Ranging Study of Intra-Arterial Thrombolysis in Acute Middle Cerebral Artery Distribution Thromboembolic Stroke (PROACT 1), 1994-1996.
9. Co-investigator - ACE Trial. NIH, March to November 1995
10. Principal Investigator - North American Symptomatic Carotid Endarterectomy Trial NIH/NINDS (NASCET), 1995-1997
11. Principal Investigator - ANCROD Study, 1996-July 1997
12. Principal Investigator - Eliprodiol-LES02, 1996-1997
13. Principal Investigator - FIS-BISS, 1996-1998
14. Principal Investigator - BAYX 3702, 1996-1998

15. Co-Principal Investigator - APPLAUD Trial, 1997
16. Principal Investigator - TAIST TINZAPARIN in Acute Ischemic Stroke-Leo Labs, Sept 1997-June 1999.
17. Principal Investigator - FIBLAST Acute Stroke Study, Wyeth Ayerth 1997-1998
18. Principal Investigator - POST BMS Acute Stroke Trial CN123-011, BMS 1998-2000
19. Principal Investigator - SPARCL Study, 1998-present
20. Principal Investigator - VISP (NIH Funded), 1998-2002
21. Principal Investigator - Citicoline Protocol IP302-018, 1998
22. Principal Investigator - BRAVO – SKB, 1999-2001
23. Principal Investigator - STAT (ANCROD), 1997-1998
24. Principal Investigator - GAINS Americas, Glaxo Welcome June- December 1999
25. Principal Investigator – CLASS 1. ASTRA-Clomethiazole Stroke Trial, 1999
26. Co-Investigator - WASID Study (NIH Funded), 1999-2004
27. Principal Investigator- MATCH. Sanofi-Synthelabo, December 2001-April 2002
28. Principal Investigator - REOPRO Trial in Acute Stroke, June 2000-April 2002
29. Principal Investigator- EKOS IA US Device. EKOS Corp, March 2000-September 2001
30. Co-Investigator - ARGIS 1. TEXAS Biotech, January 2001-May 2002
31. Principal Investigator - E2020 Aricept in Vascular Dementia Eisai, May-December 2002
32. Principal Investigator - CHARISMA. Sanofi-Synthelabo, January 2003
33. Principal Investigator - ARTIST. Yamanouchi, April 2002- February 2003
34. Principal Investigator - Repinotan in the Treatment of Acute Stroke, 2000-2004
35. Principal Investigator - ASTIN, NIF for the Treatment of Acute Stroke (Pfizer), 2000-2001
36. Co-Investigator - IMS, Combined IV/IA t-PA for Stroke, NIH/NINDS 2001
37. Co-Investigator - IMS II NIH/NINDS 2003-2005
38. Principal Investigator - PROACT II Abbott, February 1997-August 1998
39. Principal Investigator - SPORTIF, Thrombin Inhibition in Atrial Fibrillation, 2001-2002
40. Principal Investigator - REACT, ONO-2506, ONO Pharma December 2002-2005
41. Co-Investigator - F7ICH-137. NovoSeven in hemorrhagic stroke, Jan 2003-June 2004
42. Principal Investigator - AbESTT (I) Eli Lilly, June 2000-April 2002
43. Principal Investigator - CHIEF Boehringer-Ingelheim 2004. Cancelled.

44. Principal Investigator – AbESTT (II) Eli Lilly, May 2004
45. Principal Investigator - SAINT (II) AstraZeneca, July 2004
46. Principal Investigator - CHANT AstraZeneca, February 2005
47. Principal Investigator - CHIEF Boehringer Ingelheim, 2004
48. Principal Investigator - V10153 Vernalis. 2005
49. Co-Investigator - F7ICH-1641 NovoNordisk, 2005
50. Principal Investigator - DIAS 2 Forest Research/PAION, 2005
51. Principal Investigator - ACTIVE Sanofi-Synthelabo, 2004
52. Principal Investigator - PREVAIL Sanofi-Aventis, February 2005-May 2005
53. Principal Investigator - CREST NIH, May 2005-Ongoing
54. Principal Investigator - CLOSURE I NMT Medical, December 2004-present
55. Principal Investigator - FASTER, University of Calgary November 2003-present
56. Principal Investigator - Burst Study, Sponsored by Canadian Stroke Network
57. Investigator - FAST NovoNordisk, 2005
58. Principal Investigator - VASST Acute Stroke Trial, Vernalis 2006
59. Principal Investigator - PERFORM Study, Servier 2006
60. Principal Investigator - Carneros Study, Nuvelo 2007
61. Co-investigator - IMS III NIH/University of Cincinnati, 2007
62. Principal Investigator - INTERSTROKE STUDY, McMaster University 2007
63. Principal Investigator - Magellan Trial, 2008
64. Principal Investigator - Stem Cell Research Clinical Trial
65. Principal Investigator - ALIAS 2009
66. Principal Investigator - RESPECT
67. Principal Investigator - ALIAS-2
68. Principal Investigator - CREST
69. Co-investigator - DOUBT
70. Co-investigator – EMBRACE
71. Principal Investigator – CREST 2
72. Co-investigator - INTERRSeCT

- 73. Principal Investigator - REDUCE
- 74. Co-investigator - SPOTLIGHT
- 75. Co-investigator - TEMPO

(b) *Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Sanofi-Winthrop	CAPRIE study	NC	65,000		Dr. P. Teal	
Abbott	PROACT study	NC	60,000		Dr. P. Teal	Dr. D. Graeb Dr. T. Marotta Dr. J. Lapointe
Ciba-Geigy	Selfotel study	NC	60,000		Dr. P. Teal	Dr. J. Beckman
NIH	NASCET	C	40,000		Dr. P. Teal	
Knoll	ANCROD	NC	20,000	1996	Dr. P. Teal	
Loxex	Eliprodil-LES02	NC	10,000	1996	Dr. P. Teal	
Bayer	BAYX 3702	NC	80,000	1996	Dr. P. Teal	Dr. J. Beckman
Sanofi-Winthrop	FIS-BISS	NC	20,000	1996	Dr. P. Teal	Dr. J. Beckman

(c) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Bayer	Bay X-3702	NC	\$275,000	1997	Dr. P. Teal	Dr. J. Beckman
Abbott	PROACT Stroke Trial	NC	\$ 60,000	1997	Dr. P. Teal	Dr. D. Graeb
Leo	TINZAPARIN	NC	\$ 10,000	1997	Dr. P. Teal	Dr. J. Beckman
Interneuron	Citicoline	NC	\$150,000	1999	Dr. P. Teal	Dr. J. Beckman Dr. A. Woolfenden
BMS	CN123-011	NC	\$125,000	1999	Dr. P. Teal	Dr. J. Beckman Dr. A. Woolfenden
NIH	VISP	C	\$ 75,000	1999	Dr. P. Teal	Dr. A. Woolfenden
ASTRA	CLOMETHIAZOLE	NC	\$ 25,000	1999	Dr. P. Teal	Dr. A. Woolfenden
GLAXO	GAINS AMERICAS	NC	\$ 50,000	1999	Dr. P. Teal	Dr. J. Beckman Dr. A. Woolfenden
Parke-Davis	SPARCL	NC	\$ 30,000	1999	Dr. P. Teal	Dr. A. Woolfenden

NIH	WASID	C	\$ 30,000	1999	Dr.A.Woolfenden	Dr. P. Teal
SKB	BRAVO	NC	?	1999	Dr. P. Teal	Dr. A. Woolfenden
Bayer	Repinotan	NC	\$250,000	2001	Dr. P. Teal	Dr. A. Woolfenden
NIH	EMS	C	\$ 30,000- \$ 40,000	2001	Dr.A.Woolfenden	Dr. P. Teal
Astra-Zeneca	SPORTIF	NC	\$ 50,000	2001	Dr. P. Teal	Dr. A. Woolfenden

An update of clinical trial proceeds is under preparation.

9. TALKS

1992-2007 Talks available upon request

2008 (incomplete list)

March 8 Stroke and Lipids
Asian Stroke Meeting
Siem Reap, Cambodia

June 13 New Evidence in Stroke Prevention
5th Annual Champlain Regional Stroke Update
Ottawa, Ontario

June 18 PRoFESS Results and Implications for Practice
Canadian Neurological Sciences Federation 43rd Annual Meeting
Victoria, British Columbia

Sept 15 Antithrombotic Therapy Update
Ontario Stroke Conference
Toronto Ontario

Oct 4 Antiplatelet Therapy in Stroke Prevention
National Stroke Conference
Toronto, Ontario

Oct 5 TIA and Stroke Prevention
21st Annual BC College of Family Physicians Annual Scientific Assembly
Kelowna, British Columbia

Oct 25 Drugs Active on the RASS system – the Evidence in Stroke Prevention
Management of High Risk Patients, Recent Advances and Clinical Implications
Satellite Symposium
Canadian Cardiovascular Congress Annual Meeting
Toronto, Ontario

Oct 25 Oral Antiplatelet Therapy in Stroke Prevention
The Evolution of Stroke Prevention

Satellite Symposium
Canadian Congress of Cardiology Annual Meeting
Toronto, Ontario

Oct 30 Carotid Disease – Current Medical and Interventional Management
Korean Stroke Society Annual Meeting
Seoul, Korea

2009 (incomplete list)

Sept 24 Migraine & Other Common Headache Disorder - Talk to Tri City GPs
Coquitlam, BC

Oct 21 “State of the Art Stroke Prevention”
Burnaby, BC

Nov 14 6th Annual Diabetes Symposium
“Cerebrovascular Disease & Diabetes”
Vancouver, BC

Nov 8 Antiplatelet Update – The Profess Study
Canadian Stroke Consortium
Annual Investigators Meeting
Toronto, Ontario

Nov 15 Keynote Address: Cerebrovascular Disease and Diabetes
6th Annual Live Well with Diabetes Conference
University of British Columbia
Vancouver, BC

2010 (incomplete list)

Jan 13 Stroke Talk
Audience; Internal Medicine Journal Club
North Vancouver, BC

Jan 26 BCSS Telelearning Series
Co-presenter

Jan 28 “State of the Art Stroke Prevention”
Vancouver, BC

Feb 9 “State of the Art Stroke Prevention”
Vancouver, BC

April 28 Current Management of Carotid Disease
City Rounds, GF Strong

May 27 “State of the Art Stroke Prevention”
Victoria, BC

June 5 Management of Atrial Fibrillation – A Neurologists Perspective
Toronto, ON

June 8 Atrial Fibrillation, The Role of Dabigatran
Quebec City

- Sep 13 "Telestroke and Acute Stroke Management" for the White Rock Emergency Physicians and Internists - Vancouver, BC
- Sep 14 "Stroke – Clinical Care & Research" for the Vancouver Hospital Board Vancouver, BC
- Oct 16 2010 UBC Atrial Fibrillation Symposium, "Advances in Stroke Prevention in Atrial Fibrillation"
- Nov 25 "The Present & Future of Stroke Prevention in Atrial Fibrillation," SHIFT Program

2011 (incomplete list)

- Feb 2 Stroke Update: Family Physicians Vancouver, BC
- Feb 3 Stroke Update: Family Physicians Abbotsford, BC
- Feb 5 Stroke Update: Family Physicians Burnaby, BC
- Feb 8 Stroke Update: Family Physicians Los Angeles, CA
- Feb 23 Stroke Update: Family Physicians Surrey, BC
- Feb 24 Stroke Update: Family Physicians Victoria, BC
- Feb 25 Stroke Update: Family Physicians Kelowna, BC
- Jun 15 Cerebral Venous Thrombosis 2011 – invited speaker
46th Congress of Canadian Neurological Sciences Federation
Vancouver, BC

(e) *Other Presentations*

See Attached

(f) *Other*

- Oct 26 Canadian Cardiovascular Congress
Presentation
Vancouver Convention Centre, Vancouver BC

2012

- Feb 01 International Stroke Congress
New Orleans, LA
- Feb 20 Stroke Update: Family Physicians
Surrey/White Rock, BC
- Mar 07 Stroke Update: Family Physicians
Vancouver, BC

Mar 23	Stroke Review course for Neurology Residents “Acute Stroke Management and Thrombolysis” Toronto, ON
Mar 29	Stroke Update: Family Physicians Prince George, BC
Apr 16	Thrombosis Global Therapeutic Expert Forum New York, NY
May 02	Stroke Update with Dr. Kenneth Gin and Dr. Charles Constantine Audience: Fraser Valley Specialists Langley, BC
May 08	Stroke Update: Dr. Hui Journal Club Richmond, BC
Jun 08	National Heart Institute of Ha Noi Strategies for Stroke Prevention in Atrial Fibrillation Ha Noi, Vietnam
Jun 12	Stroke Update: Victoria Specialists Victoria, BC
Jun 15	Cardiac Update Talk Regina, SK
Jun 19	Stroke Update: Family Physicians North Vancouver, BC
Jun 27	Stroke Update: Family Physicians Vancouver, BC
Jul 26	Vancouver Regional Blood Club New Oral Anticoagulants – Evidence vs Practice Vancouver, BC
Sept 21	Forefronts of Neurology – Stroke Update Whistler, BC
Sept 27	Stroke Update: Hospital Business Group Surrey, BC
Sept 29	Canadian Stroke Congress “ Calgary, AB
Oct 03	Neuroscience Rounds “ Vancouver, BC
Oct 30	Stroke Update: Dr. Karmali Journal Club Maple Ridge, BC
Oct 31 & Nov 7	Department of Medicine, Grand Rounds “CCS Atrial Fibrillation Guidelines” Vancouver General Hospital, Vancouver, BC

- Nov 01 Stroke Update: Family Physician
White Rock, BC
- Nov 20 St. Paul's Hospital CME
Vancouver, BC
- Nov 20 Stroke Update: Dr. Myckantyn Journal Club
Richmond, BC

2013

- Mar 25 Apixaban Expert Meeting
Vancouver, BC
- Apr 17 ACHIEVE Lecture
Case Presentation, Challenging Clinical Questions Discussion
Vancouver, BC
- Apr 18 Stroke Prevention in Atrial Fibrillation
"New Evidence/Options in Anticoagulation"
White Rock, BC
- Apr 27 Kuwait Neurology Conference
Preventative Measures of Stroke & TIA
Kuwait City, Kuwait
- Apr 28 Kuwait Neurology Conference
Stroke in Pregnancy
Kuwait City, Kuwait
- Oct 31 Cerebrovascular Complications of Pregnancy & Puerperium
BC Women's Hospital
Vancouver, BC
- Nov 23 New Oral Anticoagulants in Atrial Fibrillation
Western Canadian Stroke Conference
Vancouver, BC
- Stroke in Pregnancy
Western Canadian Stroke Conference
Vancouver, BC

2014

- Apr 3 Speaker Bureau
Vancouver, BC
- May 14 Anticoagulation Talk, NOACs in AF
Vancouver, BC
- Jun 10 ACHIEVE, Dinner Talk
Vancouver, BC
- Jul 15 Stroke in Pregnancy,
Cerebrovascular Conference
Vancouver General Hospital

Aug 9/10

Clinical Dilemmas in SPAF; current challenges & unmet needs
Asia Pacific SPAF Expert Forum
Taipei, Taiwan

Apixaban in the Clinic; guidance for use in practice
Asia Pacific SPAF Expert Forum
Taipei, Taiwan

Unmasking the AF Patient & the Role of Apixaban
Asia Pacific SPAF Expert Forum
Taipei, Taiwan

10. **CONFERENCE PARTICIPATION (Organizer, Keynote Speaker, etc.)**

1. Chairman, Conference on Stroke Prevention, Kananaskis, AB - November 1994
2. Chairman, Conference on Threatened Stroke: Spotlight on Prevention, Vancouver B.C. - April 1995
3. Co-Chairman, Acute Stroke: The Brain Attack Paradigm, Montreal PQ - September 1996
4. Chairman, World Congress of Neurology, Stroke Poster Session, Buenos Aires -
5. Co-Chairman, National Stroke Association 3rd Annual Meeting, Montreal, PQ - September, 1997. Thrombolysis in Acute Stroke
6. Chairman, Patent Foramen Ovale and Stroke. American Heart Association Annual Stroke Meeting, Orlando, Florida - April, 1998
7. Chairman, Cerebrovascular Disease Clinical, American Academy of Neurology - April, 1998
8. Speaker, Meeting Highlights Session, American Academy of Neurology 50th Annual Meeting - April, 1998.
9. Co-Chair and Organizer. British Columbia Stroke Meeting Vancouver, B.C. October 1999.
10. Co-Chair and Organize. British Columbia Stroke Meeting Vancouver BC. October 2000.
11. Chair and Organizer
Implementing Stroke Prevention into Clinical Practice
June 16, 2001
Canadian Congress of Neurological Sciences Annual Meeting
12. Course Organizer and Chair
Stroke Care 2002 – Prevention and Treatment
CCNS Annual Meeting and Stroke Teaching Course
Joint Meeting with the Australian Neurosciences Society
Vancouver, BC
13. Co-Chair and organizer
8th International Symposium Thrombolysis and Acute Stroke Therapy
Whistler, British Columbia
14. Organizing Committee 5th World Stroke Congress
Vancouver BC.
June 23-26th 2005-08-31
15. Scientific Program Committee
5th World Stroke Congress
16. Co-Chair Satellite Symposium
Management of Cerebrovascular Disease – New results and new perspectives
5th World Stroke Congress
Vancouver BC
June 24th
17. Co-Chair, Plenary Session. Acute Stroke
5th World Stroke Conference
Vancouver Canada
June 24th, 2004

18. Chair, Satellite Symposium
Neuroprotective Therapy – Where do we go from here?
5th World Stroke Congress
Vancouver BC
June 24th, 2004
19. Planning/curriculum Committee
November 2004
Vancouver, BC
20. Annual National Neurology Residents Stroke Program
21. First National Stroke Conference
Content and faculty committee
Content and curriculum committee
January, 2005
22. Leading Stroke Experts Workshop Advisory Board Meeting
Oct. 6-8, 2005
Montreal Canada
23. Co-Chair Teaching Course: Acute stroke and Interventional Stroke
World Congress of Neurology
Sydney Australia
November 6, 2006
Co-chair and Speaker
24. Co-Chair Stroke-in-Evolution. Sponsored by University of Calgary
Lake Louise, Alberta February 3-5, 2006
25. Planning/curriculum Committee
Second National Stroke Conference
Jan. 2006
26. Planning Committee
Annual National Neurology Residents Stroke Program
Oct. 2006
Speaker: Antithrombotic therapy
27. Stroke Experts Workshop
CO-chair and speaker
ESPRIT study – What does it mean?
Cape Town, South Africa
October 24-25th 2006
28. Scientific Advisory Committee and meeting planning committee
World Stroke Conference
Cape Town South Africa
Co-Chair Plenary Session – Acute Stroke Management
Speaker – Management of Physiological Parameters in Acute Stroke
October 26-29th, 2006
29. Meeting Chair and meeting organizer
Speaker: New Developments in Antithrombotic Therapy
Vancouver, BC
November 25th, 2006
30. TAST – 9th Thrombolysis and Acute Stroke Treatment Conference
Chair – Plenary Session Acute Thrombolysis Treatment
Speaker – Novel Thrombolytic Agents – Stroke Research
December 2nd, 2006 Chair and Meeting Organizer
31. Co-Chair CNSF Scientific Program Committee
CSC Stroke Course - Vancouver, BC
October 2011
32. Co-Chair of the Annual Western Stroke Conference 1999 – 2004
33. Chair & Meeting Organizer of the Western Stroke Conference 2005 – 2013
Vancouver, BC

11. SERVICE TO THE UNIVERSITY

- (a) *Memberships on committees, including offices held and dates*
1. Neurology Residence Committee, Member 1993-2007
- (b) *Other service, including dates*
1. Teaching > 50 hours annually
 2. Conduct weekly stroke rounds for resident education
 3. Annual participation in Brain and Behaviour teaching
- (c) Clinical Faculty Committee Representative
Department of Medicine, 2006-

12. SERVICE TO THE COMMUNITY

- (a) *Memberships on scholarly societies, including offices held and dates*
1. American Academy of Neurology, 1987 to present
 2. American Heart Association - Stroke Council, 1989 to present
 3. British Columbia Medical Association, 1975 to present
 4. Canadian Medical Association, 1975 to present
 5. Canadian Stroke Society - B.C. Delegate & Regional Representative, 1994 to present
 6. Canadian Stroke Consortium – Executive/BOARD Committee, 1994 to present
 7. Royal College of Physicians & Surgeons (Canada), 1983 to present
 8. International Stroke Society – Board Member 2004-2007
 9. World Stroke Federation - Board Member 2004-2007
 10. Thrombosis Interest Group of Canada 2003-
 11. World Stroke Organization Board Member 2008-
- (b) *Memberships on other societies, including offices held and dates*
1. National/International Advisory Board to the WHO COLLABORATING CENTRE for Research on Stroke Prevention and Epidemiology - May 1994 to 1997
 2. Board, Stroke Recovery Association of British Columbia 1999 to present\
 3. Board, Heart and Stroke Foundation of Canada, 2006 -2009
 4. VANCOUVER HOSPITAL FOUNDATION – BOARD MEMBER
- (c) *Memberships on scholarly committees, including offices held and dates*
1. Canadian Stroke Society - B.C. Delegate & Regional Representative, 1994 to present
 2. Canadian Stroke Consortium - Executive Committee, 1994-97
 3. Canadian Stroke Consortium - Board of Directors, 1997 to present
 4. Heart & Stroke Foundation - Grant Review Committee, 1998-99
 5. Board Member Heart and Stroke Foundation of BC and the Yukon 2002-5
 6. Canadian Stroke Consortium – Vice Chairman 1999-2001
 7. Chairman, Canadian Stroke Consortium 2001 to present
 8. International Stroke Society Board 2004 to present
 9. International Stroke Society Fund Raising Committee 2004 to present
 10. International Stroke Society. Interventional Stroke Therapy Committee 2004- present
 11. World Stroke Federation Board 2004 to present
 12. Western Vascular Society Board, 2004 to present
 13. Western Stroke Society Board, 2005 to present
 14. International Scientific Program Committee. 8th International Symposium Thrombolysis and Acute Stroke Therapy. 2002-4
 15. Canadian Stroke Society Board Ex-officio 2005-
 16. International Advisory Board – 6th World Stroke Congress Vienna Austria 2008

(d) Memberships on other committees, including offices held and dates

1. Chairman, 1979-1982 Parkside Emergency Physicians
2. Chairman, 1979-1982 Emergency Services Department, Royal Jubilee Hospital
3. Chairman, 1979-1982 Emergency Services/Disaster Committee, Victoria General Hospital
4. Member, 1983-1984 General Practice Executive Committee, Royal Jubilee Hospital
5. Member, 1983-1984 Capital Regional District Health Planning Committee
6. Member, 1998 Vancouver General Hospital, Bed Aggregation Committee
7. Member, 1998 ROARS Committee
8. Chairman, 1998-2000 Heart & Stroke Association of B.C. Acute Stroke Management Committee
9. Heart and Stroke Society of BC and Yukon, Stroke Advisory Committee 2005 to present
10. World Stroke Day Proclamation – Writing committee 2004- present
11. Chairman, Canadian Stroke Consortium, 2002-Present.
12. Regional Stroke Strategy Leadership Committee – Vancouver Coastal Health Region 2006 –
13. Member, 2007 – BC Stroke Strategy Committee
14. Chair, BC Telestroke Committee
15. Member VCH Stroke Leadership Committee
16. Stroke Leadership Committee Vancouver Coastal Health 2008-
17. BC Stroke Strategy Committee 2008-
18. Chair, BC Telestroke Committee - 2012 -
19. BCSS Advisory Committee 2012-
20. VCH ACVS STEERING COMMITTEE

13. STEERING COMMITTEE MEMBERSHIP – International Clinical Trials

PRoACT III
 BRAINS – Chair International Steering Committee
 mRECT-Chair International Steering Committee
 rREACT ONO Neuroprotection Trial
 ASTIN
 AbESTT II Executive Committee Triad 2004 to present
 DIAS II – 2004 to 2008
 ARCH 2004- present
 CHARISMA- National Coordinator 2003- 2007
 PRoFESS 2003- 2008
 SB737004 Shiongi-GlaxoSmithKline Pharmaceuticals LLC 2004 - 2007
 CASTIA 2005-2006
 PERFORM 2006-present
 Nuvelo Acute Interventional Stroke Study- 2006-2008
 INTERSTROKE McMaster University 2007
 VASTT trial 2007
 FASTER II 2008

14. DATA and SAFETY MONITORING COMMITTEE MEMBERSHIP

RIS-USA-232 DSMB 2002-2003
 EVEREST STUDY 2005-

15. EDITORSHIPS

1. International Abstracts in Stroke - October 1993 to 2002

2. Editorial Board International Journal of Stroke 2005- ongoing

16. AD HOC REVIEWER

1. Canadian Journal of Neurosciences
2. Journal of Movement Disorders
3. Heart and Stroke Foundation Research Grants
4. STROKE
5. Cerebrovascular Diseases 2000- present
6. Canadian Stroke Consortium Clinical Trial Review Committees. As Chair of the CSC I participate as a committee member for all research projects conducted by the Canadian Stroke Consortium. This entails 3-6 project reviews annually. Formal review reports are written.

17. CONSULTANT/ADVISORY BOARD

1. Senior Medical Consultant
Emergency Health Services Commission
Ministry of Health, British Columbia 1985-86
2. Steering Committee, BRAINS Trial (Bay X-3702)
3. Steering Committee, CARINE Trial (Clopidogrel vs. Aspirin in Reversible Ischemic Neurological Events)
4. Hoffmann-LaRoche 1996-
5. Janssen Pharma 1996-2003
6. Sanofi Pharma 1997-
7. Boehringer-Ingelheim 1998-
8. External Scientific Selection Advisory Committee – Phoenix BioPharm Inc August 2005 – ongoing
9. Merck (ongoing)
10. Pfizer (ongoing)
11. Solvay 2005-
12. BMS/Sanofi New York Sept 26, 2005
13. BAYER 2005-
14. NOVO-Nordisk 2005-

18. OTHER SERVICE TO THE COMMUNITY

1. Annual Public Awareness talks
2. Annual appearance on Art Hister's House Calls
3. Board member, Stroke Recovery Association of British Columbia

19. AWARDS AND DISTINCTIONS

- (a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

Award for the Outstanding Grand Medical Rounds 2004

Best Role Model/Example of Professionalism 2010

PAR-BC 2010, Dr. Patricia Clugston Memorial Award for Excellence in Teaching

Master Teacher Award, University of British Columbia Department of Medicine 2014

- (b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

E.L. Pope Memorial Award in Medicine

**University of Alberta Medical School
Class standing 2/112
June, 1974**

**The Sauder Family Heart and Stroke Foundation Professorship in Clinical Stroke Research
Awarded in 2006
Announcement Pending.**

**The Fay R Dirks Award
Excellence in Teaching
University of British Columbia
June, 2007**

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

(d) *Other Awards*

**Selected to "The Best Doctors in America"
Woodward/White Inc, 1998**

Best Doctors in Canada 2007-8

**Bringing Clinical Renown to Vancouver Acute 2014
Vancouver Coastal Health**

20. RESEARCH GRANTS or EQUIVALANTS

1. B.C. Heart and Stroke Clinical Stroke Fellowship Grant 1991-1992
25,000/year to support stroke fellowship at Tufts University Boston
2. VGH UBC Foundation 2005 \$48,000
Effect of Asymptomatic Unilateral Severe Carotid Stenosis on Brain Tissue
Perfusion/Oxygenation during Cardiopulmonary Bypass
Principal investigator: Dr Jian Ye
Co-Investigator: Dr. Philip Teal and others

21. REFEREED PUBLICATIONS

(a) *Journals*

1. Teal PA. Management of Alcohol Withdrawal Syndromes. British Columbia Medical Journal, 28:8:520-522, September 1987.
2. Wolters E, Hurwitz T, Mack E, Teal PA, Peppard R, and Calne DB. Clozapine in the Treatment of Parkinson's Patients with Dopaminergic Psychosis. Neurology, 40(5):832-834, 1990.
3. Peppard R, Chim-Song L, Teal PA, Martin W, and Calne DB. Parkinsonism with Neuro-Acanthocytosis. Decreased Striatal F-6-Fluorodopa Uptake Demonstrated with Positive Emission Tomography, Canadian Journal of Neurosciences, 17(3):298-301, 1990.
4. Appelton R, Farrell K, Teal PA, and Hashimoto SA. Partial Complex Status Epilepsy Associated with Cyclosporin A. Journal of Neurology, Neurosurgery and Psychiatry, 52:1068-1071, 1989.
5. Pessin MS, Teal PA. Hemorrhagic Infarction: Guilt by Association? AJNR, 12:1123-1126, 1991.

6. Caplan LR, Rosengart A, Teal PA, DeWitt LD, Pessin MD, Amarenco P. Embolism from vertebral artery origin occlusive disease. *Neurology* 42 (Suppl 1):381, 1992.
7. Rosengart A, Pessin MS, Caplan LR, Wityk RJ, Teal PA. Extracranial Vertebral Artery Disease in Acute Vertebrobasilar Ischemia.
8. Caplan LR, Amarenco P, Rosengart A, LaFranchise EF, Teal PA, Belkin M, DeWitt LD, Pessin MS. Embolism from Vertebral Artery origin occlusive disease. *Neurology* 42:1505-1512, 1992.
9. Chaves C, Chung CS, Caplan LR, Amarenco P, Rosengart A, Wityk R, Teal PA, Vemmos K, Pessin MS. Cerebellar Infarcts - Boston and Taejon, Korea Series: Localization and Clinical Findings. *Stroke*.
10. Caplan LR, Teal PA. The Moving Embolus - a case report. *Journal of Neuroimaging* 1993;3:195-197.
11. Rosengart A, Hedges TR, Teal P et al. Intermittent downbeat Nystagmus due to Vertebral Artery Compression. *Neurology* 1993;Jan;43(1):216-8.
12. Chaves CJ, Caplan LR, Chung CS, Tapia J, Amarenco P, Teal PA, Wityk R, Estol C, Tettenborn B, Rosengart A, Vemmos K, DeWitt LD, Pessin MS. Cerebellar infarcts in the New England Medical Center Posterior Circulation Stroke Registry. *Neurology* 44:1385-1390, 1994.
13. Chen JC, Salvian AJ, Taylor DC, Teal PA, Marotta TR, Hsiang YN. Predictive Ability of Duplex Ultrasonography for Carotid Artery Stenosis of 70-99%: A Comparative Study. *Cardiovascular Surgery*. October, 1996. Vol. 4, No. 5.
14. Salvian AJ, Taylor DC, Hsiang YN, Hildebrand HD, Litherland HK, Humer MF, Teal PA, MacDonald DB. Selective shunting with EEG monitoring is safer than routine shunting for carotid endarterectomy. [Journal Article] *Cardiovascular Surgery*. 5(5):481-5, 1997 Oct.
15. Turnbull RG, Tsang VT, Salvian AJ, Teal PA. Thrombectomy for Paradoxical Inominate Artery Embolus. *Journal of Vascular Surgery*. *Journal of Vascular Surgery*. 28(4):742-5, 1998 Oct. .
16. Teal PA. Prehospital Management - Referral Patterns to Hospitals. *Revista Neurologica Argentina*, 22, Suppl 1;7, 1997.
17. Chen JC, Salvian AJ, Taylor DC et al. Can duplex ultrasonography select appropriate patients for carotid endarterectomy? *Eur J Vasc Endovasc Surg* 1997 Dec;14(6):451-6.
18. Singh RB, Graeb DA, Fung, A, Teal PA. Cardiac Rupture Complicating Cerebral Intra-arterial Thrombolytic Therapy. *AJNR* 18:1881-1883, Nov 1997.
19. Barnett HMJ, Taylor DW, Eliaszew M et al for the NASCET Investigators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *NEJM* 1998;339:1415-25.
20. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. *CHEST* 1998; 114/5 November 1998 supplement: 683S-799S.
21. Norris JW, Buchan A, Cote R, Hachinski V, Phillips SJ, Shuaib A, Silver F, Simard D, **Teal P**. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium. *Canadian Journal of Neurological Sciences*. 25(3):257-9, 1998 Aug.
22. Chen JC, Salvian AJ, Taylor DC, Teal PA, Marotta TR, Hsiang YN. Valeur de l'Echographie-Doppler pour Characterizer les Stenoses Carotidiennes comprises entre 70% et 99%: Une Etude Comparative. (*Ann chir Vasc* 1998; 12:244-247).
23. Chen JC, Salvian AJ, Taylor DC, Teal PA, Marotta TR, Hsiang YN. Predictive Ability of Duplex Ultrasonography for Internal Carotid Artery Stenosis of 70%-99%: A Comparative Study. (*Ann Vasc Surgery* 1998; 12:244-247).

24. Hakim A, Lebrun L, Phillips S, Shuaib A, Teal P et al
Factors influencing destination after hospitalization for acute stroke in five Canadian tertiary care centres
Canadian Journal of Neurological Sciences 1998; 25: Suppl – S81 (Abstract)
25. Turnbull RG, Tsang VT, Teal PA, Salvian AJ. Successful Innominate Thromboembolectomy of a Paradoxical Embolus. J Vasc Surg 1998 Oct; 28(4):742-5.
26. Teal P on behalf of BRAINS study group.
BRAINS, a Phase II study of the neuroprotectant BAY x3702 in patients with ischemic stroke
Cerebrovascular Diseases 1998; 8: Supplement 4 S20.
27. Winkelaar GB, Salvian AJ, Fry PD, Reid JDS, Teal PA, Taylor DC, Hsiang YN. Intraoperative Intra-arterial Urokinase in Early Postoperative Stroke following Carotid Endarterectomy: A Useful Adjunct. (Ann Vasc Surg 1999; 13:566-570).
28. Winkelaar GB, Chen JC, Salvian AJ et al. New Duplex Ultrasound Scan Criteria for Managing Symptomatic 50% or Greater Carotid Stenosis. J Vasc Surg 1999 Jun; 29(6):986-94.
29. Chapman KM, Woolfenden AR, Graeb D, Johnston DCC, Beckman J, Schulzer M, Teal PA: Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke: A Canadian Hospital's Experience. Stroke 2000;31:2920-4
30. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M and the PROACT Investigators including Teal PA. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. (Stroke. 1998; 29:4-11.)
31. Turnbull EG, Tsang VT, Teal PA, Salvian AJ. Successful innominate thromboembolectomy of a paradoxical embolus. J Vasc Surg 1998;28:742-5
32. Furlan A, Higashida R, Wechsler L et al and the PROACT Investigators including Teal PA. Intra-arterial Pro-urokinase for Acute Ischemic Stroke. The PROACT II Study. A Randomized Controlled Trial. (JAMA. 1999; 282:2003-2011.
33. Multiple Contributors including Teal, P. Recommendations for Improving Clinical Trials Design and Endpoint Selection. Stroke Therapy Academic Industry Roundtable II (STAIR II).
34. Hill, MD, Woolfenden A, Teal P, Buchan AM. Intravenous Alteplase for Stroke: The Canadian Experience. The Stroke Interventionalist 2000; Volume II, Issue 2:5-8.
35. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. CHEST February 2001.
36. Stroke Therapy Academic Industry Roundtable II. Recommendations for clinical trial evaluations of acute stroke therapies. Statement contributor. Stroke 2001;32:1598-1606.
37. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, Marra CA. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. [Journal Article] *pharmacoeconomics*. 19(9):927-36, 2001.
38. Mahon BR, Nesbit GM, Barnwell SL, Clark W, Marotta TR, Weill A, Teal PA, Quershi AI. North America clinical experience with the EKOS MicroLys US infusion catheter for the treatment of embolic stroke. Neurology 2003; 24:534-8.
39. Fisher M et al including Teal P for Stroke Therapy Industry Academic Round Table. Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic industry roundtable 3. Stroke 2003;34:1539-1546.

40. Krams J, Lees KR, Hacke W et al. (Teal P Investigator, contributor, steering Committee.) Acute stroke therapy by inhibition of neutrophils (ASTIN) *Stroke* 2003; 34:2543-2548.
41. Teal PA. Recent clinical trial results with antiplatelet therapy implication in stroke prevention. *Cerebrovascular Diseases* 2004;17 Suppl 3:6-10.
42. Woolfenden AR, Teal PA, Wade NK, Tang P, Chalmers A, Reid G. CNS Vasculitis Uveitis Syndrome. *Canadian J of Neurol Sciences* 2004.
43. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. The seventh ACCP Conference on the Antithrombotic and thrombolytic therapy. *CHEST* 2004;126:483S-512S.
44. Toole JF, Malinow MR, Chanbless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. *JAMA* 2004;291:565-75.
45. Caplan LR, Whityk RJ, Glass TA, Tapia J, Pazdera L, Chang HM, Teal P, Dashe JF, Chaves CJ, Breen JC, Vemmos K, Amarenco P, et al. New England Medical Center Posterior Circulation registry. *Ann Neurol*. 2004;56:389-98.
46. Hill MD, Buchan AM, for the CASES Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for stroke effectiveness study. *CMAJ* 2005;172:1307-12.
47. Teal P, Silver FL, Simard D. Safety, Tolerability, and Dose-finding of Repinotan in Acute Stroke. *The Canadian Journal of Neuroscience*. 2005;32:61-67.
48. Muir KW, Teal PA. Why have neuroprotectants failed? Lessons learned from stroke trials. *J Neurol*. 2005 August 25;[Epub ahead of print].
49. Woolfenden AR, Wade NK, Tang P, Chalmers A, Reid G, Teal PA. Uveitis Associated with Primary Angiitis of the Central Nervous System. *Can J. Neurol. Sci.* 2007;34:81-83
50. Adams HP, Efron MB, Torner J, Davalos A, Frayne J, Teal Philip, Lerclerc, J et al. Emergency administration of Abciximab for treatment of patients with acute ischemic stroke: Results of an International Phase III Trial. *Stroke* 2008;39:87-89
51. Sacco RL, Diener HC, Yusuf S, et al including Teal P. Aspirin and Extended Released Dipyridamole vs clopidogrel for recurrent stroke. *N Eng J Med* 2008;359:1238-51
52. Yusuf S, Diener HC, Sacco RL et al including Teal, P. Telmisartan to prevent recurrent Stroke and cardiovascular events. *N Engl J Med* 2008;359:1225-37
53. Effects of aspirin plus extended-release dipyridamole versus Clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Diener HC, Sacco RL, Yusuf S, et al including Teal PA. *Lancet Neurology* Sept 2008;7:875-84
54. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Addition) *CHEST* 2008;133:630-669S
55. Saw J, Walsh SJ, Teal P et al. Carotid Artery Stenting Experience by Interventional Cardiologists in a Canadian Cardiac Catheterization Laboratory. *Canadian Journal of General Internal Medicine*. 2009, Dec
56. Teal P, Davis S, Hacke V et al. A randomized, double-blind placebo controlled trial to evaluate the efficacy, safety, tolerability and pharmacokinetic/pharmacodynamic effects of a targeted dose of intravenous repinotan in patients with acute ischemic stroke. *Stroke* 2009;40:3518-3525

57. Kamel H, Lees KR, Lyden PD, Teal PA, Shuaib A et al. Delayed detection of atrial fibrillation after ischemic stroke. *Journal of Stroke and Cerebrovascular Diseases* 2009;18:453-457
58. Schwamm LH, Leal JS, Sohngen M, Teal PA et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion- DIAS-2. *Lancet* 2009
59. Bell AD et al including Teal, Philip. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guideline Executive Summary. *Canadian Journal of Cardiology* 2011;27:208-221
60. Beadon, Katie E., Johnston, Dean, Chapman, Kristine, Gooderham, Peter A., Teal, Philip University of British Columbia, Vancouver, B.C. Canadian Neurological Federation – “Rock ‘til You Drop: Cervical Arterter Dissection in Musicians”
61. W., Furlan, A.J., Al-Rawi, Y., Davalos, A., Fiebich, J.B., Gruber, F., Kaste, M., Lipka, L.J., Pedraza, S., Ringleb, P.A., Rowley, H.A., Schneider, D., Schwamm, L.H., Leal, J.S., Söhngen, M., Teal, P.A., Wilhelm-Ogunbiyi, K., Wintermark, M., Warach, S. - Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study – Hacke S.

(b) Abstracts

1. Teal PA and Wada JA. Temporal Lobe Epilepsy with Bilateral Independent Seizure Generating Foci. *Epilepsia*, 300:5:663, September 1989.
2. Rosengart A, Wityk RJ, Teal PA, DeWitt LD, Pessin MS, Caplan LR. Clinical Angiographic Correlation in Vertebrobasilar Ischemia. *Neurology* 42 (Suppl 1):401, 1992.
3. Teal PA, Wityk RJ, Rosengart A, Caplan LR. Spinal TIAs - A Clue to the Presence of Spinal Dural AVMs. *Neurology* 42 (Suppl 1): 1992.
4. Rosengart A, Wityk RJ, Teal PA, DeWitt LD, Pessin MS, Caplan LR. Vertebrobasilar Clinical - Angiographic Correlation. *Cerebrovascular Dis* 2(4):211, 1992.
5. Rosengart A, DeWitt LD, Wityk RJ, Teal PA, Pessin MS, Wolpert S, Caplan LR. Non-invasive Tests in Vertebrobasilar Disease. *Cerebrovascular Dis* 2(4):211, 1992.
6. Rosengart A, Caplan LR, Pessin MS, Wityk RJ, Teal PA, Amarenco P. Extracranial Vertebral Artery Disease in Posterior Circulation Ischemia. *Cerebrovascular Dis* (4):238, 1992.
7. Rosengart A, Caplan LR, Amarenco P, Teal PA, Wityk RJ. Bilateral Cerebellar Infarcts. *Cerebrovascular Dis* 2(4):237, 1992.
8. Humer M, Salvian AJ, Taylor DC, Litherland, HK, McDonald D, Teal PA. EEG Monitoring in Carotid Surgery. *Canadian Journal of Surgery*, 1994.
9. Winder TR, Teal PA. Overlap Syndrome between Periodic Cerebellar Ataxias and Episodic Vestibulocerebellar Syndrome Responsive to Acetazolamide. (Abstract, in press)
10. Teal P. BRAINS, a Phase II Study of the neuroprotective BAY X3702 in Patients with Acute Ischemic Stroke. *Cerebrovasc Dis* 1998; 8(Suppl 4):20.
11. Hakim A, Lebrun L, Phillips S, Shuaib A, Teal PA, Ramsden V, et al. Factors Influencing Time from Stroke Onset to Hospital Arrival in Five Canadian Cities. *Canadian Journal of Neurological Sciences*, 25 (Suppl 2); S14, 1998.
12. Hakim A, Lebrun L, Phillips S, Shuaib A, Teal PA, Ramsden V, et al. Factors Influencing Destination after Hospitalization for Acute Stroke in Five Canadian Tertiary Care Centers. *Canadian Journal of Neurological Sciences*, 25 (Suppl 2); S81, 1998.

13. Hill MD, Barber PA, Buchan AM for the CASES Investigators including Teal PA. The Canadian Activase for Stroke Effectiveness Study (CASES) (abstract) *Stroke* 2000; 31:315.
14. Teal P, Silver F, Grotta J, et al. The Neuroprotectant BAY X 3702 in Acute Ischemic Stroke: BRAINS. *Neurology* 1999. 52; (Suppl 2):383.
15. Teal P, Rombout F, Weber H, et al. Repinotan: An Innovate Phase III Design in Stroke. *Stroke* 2000. Volume 31:2811.
16. Teal P, Clark WM, Shuaib A, et al. Intra-arterial Ultrasound Catheter (EKOS) Facilitated Thrombolysis. Presented at the 6th International Thombolysis and Acute Stroke Conference. Hamilton Island, Australia. 2000
17. Chapman KM, Teal PA. Stroke Following Lung Transplantation: A Case Report and Review of the Literature. *The Canadian Journal of Neurological Sciences* 2000; 27; (Suppl 2):S34.
18. Teal P, Yip S, Woolfenden AR et al. Surgical Closure of Patent Foramen Ovale for Stroke Prevention: Vancouver General Hospital Experience. *Stroke* 2001;32:333
19. Teal P, Rombout F, Rodriguez M-L, Cyrus P, et al. Repinotan (Bay x 3702): In Acute Ischemic Stroke: A Randomized Exposure Controlled Trial (RECT). Abstracts of the 26th International Stroke Conference. American Stroke Association. February 2001.
20. Hill MD, Barber PA, Buchan AM for the CASES Investigators. The Canadian
Activase for Stroke Effectiveness Study (CASES) *Stroke* 2000; 31: 315
21. Chapman KM, P.A. Teal PA, A. Woolfenden AR. Stroke Following Lung Transplantation: a Case Report and Review of the Literature. Presented at the Canadian Congress of Neurologic Science's Meeting, Ottawa 2000.
22. Schultz GA for the PROACT III Steering Committee, including Teal PA. PROACT III A Global Trial of IA Thrombolysis in acute (<6hours) Stroke. Presented at the 4th World Stroke Congress. Melbourne Australia 2004.
23. Teal PA, Woolfenden AR, Hill MD, Buchan AM for the CASES Investigators. Time To Treatment In The Canadian Activase For Stroke Effectiveness Study (Cases): Interim Analysis. Canadian Cardiovascular Society, Vancouver 2000.
24. Teal P, Salloway S, Correia S et al for the donepezil 307 NS 308 Study Groups. A comparison of the cognitive benefits of donepezil in patients with cortical and Subcortical vascular dementia. Presented at the 5th World Stroke Congress, Vancouver, BC June 25, 2004. Abstract published in *Stroke*.
25. Chapman KM, Woolfenden AR, Teal PA, Spacey SD. Pseudomigraine with Lymphocytic Pleocytosis: A Calcium Channelopathy? A Clinical Description of Five Cases and Genetic Analysis of the Familial Hemiplegic Migraine Gene, CACNA1A. Accepted at the Canadian Congress of Neurologic Science's Meeting, Vancouver, June 2002.
26. Woolfenden AR, Graeb D, Jain R, Hill M, Beckman J, Teal P. Reversibility of Early CT changes with IV Thrombolysis. Presented at the 27th International Joint Conference on Stroke and Cerebral Circulation, San Antonio, Tx, February 2002.
27. Teal PA. Ultrasound accelerated thrombolysis for stroke therapy. 3rd International Symposium on Sonodynamic Therapy. Fukuoka University, Fukuoka Japan March 28, 2002.
28. Mehdiratta M, Woolfenden AR, Johnston DCC, Chapman KM, Teal PA. Reduction of IV tPA Door to Needle Times with an Acute Stroke Triage Pathway. Presented at the AAN, Honolulu HI, 2003
29. Mehdiratta M, Al-Harathi A, Murphy C, Teal P. Myocardial infarction after tPA for stroke – 3 cases. Presented at the 5th World Stroke Congress. Vancouver June 2004 (Abstract published in *Stroke* proceedings).

30. Woolfenden AR, Graeb D, Jain R, Hill M, Beckman J, Teal P. Reversibility of Early CT changes with IV Thrombolysis. Presented at the 27th International Joint Conference on Stroke and Cerebral Circulation, San Antonio, TX, February 2002.
31. Savedia-Cayabyab S., Mehdiratta M., Teal P.A. A Case of Simultaneous Postpartum Cerebral Angiopathy and Vertebral Dissection. *Cerebrovascular Diseases*, Vol 13 (suppl 3), 75, 2002.
32. Teal PA. Effects of Repinotan in acute ischemic Stroke: a Phase IIb modified randomized exposure control trial (mRECT) Presented at the European Stroke Conference (Platform presentation). Bologna Italy. May 28, 2005. Published in *Cerebrovascular Diseases*.
33. Teal P, Salloway S, Correia S. et al for the donepezil 307 and 308 Study Groups. Accepted for presentation at the World Stroke Congress. Vancouver British Columbia June 2004 A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia Vancouver Hospital and Health Sciences Centre, Vancouver, Canada; ²Brown Medical School, Providence, Rhode Island, USA; ³Eisai Inc, Teaneck, New Jersey, USA
34. Teal PA, Novel Thrombolytic Agents in Acute Stroke International Journal of Stroke. 2006;1 (Suppl 2):2

(c) Chapters

1. Teal PA, Pessin MS. Hemorrhagic Transformation: The Spectrum of Ischemia-Related Brain Hemorrhages. In: Neurosurgery Clinics. Saunders WB (Ed), 1992.
2. Pessin MS, Teal PA. Carotid Territory Ischemic Stroke. In: Cerebral Vascular Disease. Fisher M (Ed), New York, Gower Medical Publishing, 1992.
3. DeWitt LD, Rosengart A, Teal PA. Normal Values. In: Transcranial Doppler Sonography, Clinical and Research Applications.
4. Pessin MS, Teal PA. Carotid Territory Ischemic Stroke. In: Clinical Atlas of Cerebrovascular Disorders. 1994.
5. Teal PA, Pessin MS. Hemorrhagic Infarction. In Neurobase. Arbor Publications. 1995.
6. Pessin MS, Teal PA. Cardinal Clinical Features of Ischemic Cerebrovascular Disease Associated with Vascular Territories. In Office Practice of Neurology. Churchill Livingstone. New York; 311-329, 1996.
7. Teal PA, Norris JW. Atherosclerotic Disease of the Carotid Arteries - Medical Considerations. In Stroke: Pathophysiology Diagnosis, and Management. Churchill Livingstone. New York. Barnett, HJM et al (Ed). 3rd Edition. 1998.
8. Teal PA. Hemorrhagic Infarction in Neurobase, Arbor Publications, 1997.
9. Teal PA. Cardinal Features of Ischemic cerebrovascular Disease in Relation to Vascular Territories. In: Office Practice of Neurology Second Edition. Churchill Livingston. New York 363-378. 2003.
10. Teal PA, Norris JW. Modern Stroke Prevention. In Cerebrovascular Disease. Raven Press. New York, 1996
11. Hill M, Demaerschalk B, Teal P, Pawsey S, et al. Vastt-the v10153 acute stroke thrombolysis trial. International Journal of Stroke Vol 3 Suppl 1:133, 2008

(d) Editorials

1. Teal, PA. Antiplatelet Therapy for Stroke Prevention. Journal Watch. Neurology. NEJM. December 2000;

2:91.

(e) *In Press*

22. NON-REFEREED PUBLICATIONS

(a) *Journals*

International Stroke Abstracts - Editor 1994-- 1998

Teal PA Stroke Prevention: The role of Statin Therapy. *Atherosclerosis in Primary Care*. September 2005

(b) *Conference Proceedings*

Antiplatelet and Antithrombotic Therapy in Cerebrovascular Disease Conference: New Frontiers With Antiplatelet Therapy, Victoria, B.C. 1995

(d) STEP – Stroke Treatment and Education Program

Co-author

Funded by Heart and Stroke Foundation of Canada and Janssen –Ortho

Next STEP

Co-author

Funded by Heart and Stroke BC

NeuroCare: Atherothrombosis Management in Your Practice

Development committee and do-author

23. WORK SUBMITTED

PFO Current Management Strategies- Submitted

24. WORK IN PROGRESS

1. Intracranial Arterial Dissections.
2. Carotid Dissection: Recognition in the Emergency Department. Case Reports and Review.
3. Spinal Cord TIAs - a Symptom of Spinal AVMs.
4. Vermal Cerebellar Hemorrhages

Philip A. Teal, MD, FRCPC

Dec 18,^h 2014